Dramatic advances in the fields of biochemistry, cell and molecular biology, genetics, biomedical engineering and materials science have given rise to the remarkable new cross-disciplinary field of tissue engineering. Tissue engineering uses synthetic or naturally derived, engineered biomaterials to replace damaged or defective tissues, such as bone, skin, and even organs.
Pall Corporation, a global leader in filtration, separation and purification, has applied for a patent with the United States Patent and Trademark Office (USPTO) for a disposable, closed cell collection and seeding system that is being developed for use in ground-breaking vein regeneration procedures.
Patients who rely on recombinant, protein-based drugs must often endure frequent injections, often several times a week, or intravenous therapy. Researchers at Children's Hospital Boston demonstrate the possibility that blood vessels, made from genetically engineered cells, could secrete the drug on demand directly into the bloodstream.
Mary Ann Liebert, Inc., publishers announces the launch of Disruptive Science and Technology, a highly innovative, bimonthly peer-reviewed journal that seeks to publish game-changing research that has the potential to significantly improve human health, well-being, and productivity.
BioTime, Inc., a biotechnology company that develops and markets products in the field of regenerative medicine, today reported financial results for the third quarter and nine months ended September 30, 2011 and highlighted recent corporate accomplishments.
In the emerging field of tissue engineering, scientists encourage cells to grow on carefully designed support scaffolds. The ultimate goal is to create living structures that might one day be used to replace lost or damaged tissue, but the manufacture of appropriately detailed scaffolds presents a significant challenge that has kept most tissue engineering applications confined to the research lab.
Technology has radically changed the way surgeons practice medicine, and nowhere is this more evident than in the field of gynecologic endoscopy. AAGL, the oldest professional organization devoted to teaching minimally invasive treatment for women's health problems, will showcase a number of innovative surgical approaches and teaching tools among the hundreds of postgraduate courses and practice labs offered at its annual Global Congress, November 6-11, 2011 at the Westin Diplomat in Hollywood, FL.
The U.S. Food and Drug Administration (FDA) has awarded the Georgia Institute of Technology, Children's Healthcare of Atlanta, Emory University and Saint Joseph's Translational Research Institute (SJTRI) a two-year, $1.8 million grant to foster the development of medical devices focused on the special needs of children.
A young scientist who led research into the use of stem cells from hair follicles to treat the ocular surface disease has been named the winner of the Young Investigator Award by the journal Stem Cells.
Scientists at the University of California, San Diego have developed what they believe to be the first polymeric material that is sensitive to biologically benign levels of near infrared (NIR) irradiation, enabling the material to disassemble in a highly controlled fashion.
Advances in tissue engineering and stem cell therapies will be among the research topics discussed during the National Institutes of Health's fourth Symposium on Cardiovascular Regenerative Medicine, which will be held Oct. 4-5.
The National Science Foundation (NSF) has awarded $6 million to fund three projects involving researchers from the Georgia Institute of Technology. Each four-year, $2 million grant was awarded through the NSF's Division of Emerging Frontiers in Research and Innovation.
Identifying the cellular origins of breast cancer might lead to earlier diagnosis and more efficient management of the disease. New research led by Charlotte Kuperwasser of Tufts University School of Medicine (TUSM) has determined that common forms of breast cancer originate from breast cells known as luminal epithelial cells while rarer forms of breast cancer, such as metaplastic carcinomas, originate from basal epithelial cell types.
The National Institutes of Health (NIH) has awarded nearly $2 million to researchers at the Georgia Institute of Technology and Emory University to develop a new class of therapeutics for treating traumatic injuries and degenerative diseases.
The Swanson School of Engineering at the University of Pittsburgh has received a $3.54 million grant from the Wallace H. Coulter Foundation.
Researchers at the University of Sheffield have developed polymers that fluoresce in the presence of bacteria, paving the way for the rapid detection and assessment of wound infection using ultra-violet light.
Fifty-two year-old Paul McNeel, a fire chief from Leonardtown, Maryland was 37 in 1996 when a sudden health problem caused the loss of his small intestine. Almost all of it had to be surgically removed to save his life. For 13 years after that, McNeel continued to fight fires and stayed alive only because he fed himself a special liquid formula through a tube that went from a port in his chest directly to his heart and into his bloodstream.
Today leading New Zealand biotechnology company Therapy Cell Ltd announced it was moving to the United States through its merger with Therapy Cells Inc (formerly DIII OTC Market). This exciting Bio Tech/Med tech Company holds the exclusive technology that allows adult cells from a specific tissue (e.g. Achilles tendon) to grow again from an individual to enact repair and regeneration of that tissue.
Researchers have been working at growing tissue and organs in the laboratory for a long time. These days, tissue engineering enables us to build up artificial tissue, although science still hasn't been successful with larger organs. Now, researchers at Fraunhofer are applying new techniques and materials to come up with artificial blood vessels in their BioRap project that will be able to supply artificial tissue and maybe even complex organs in future.
Mary Ann Liebert, Inc. announces the launch of a journal expansion, Human Gene Therapy Methods, to complement the flagship publication Human Gene Therapy.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.